glp 1 receptor agonists beyond their pancreatic effects The Multifaceted Nature of GLP-1: Molecular Mechanisms and Signaling Pathways in Metabolic and Neurodegenerative Diseases The central and peripheral effects
Description
Canada Mexico Europe Germany France U.K
Pharmacovigilance studies indicate that GLP-1RAs, with the exception of albiglutide, demonstrate potential associations with pancreatic cancer risk, particularly evident in exenatide-treated patients who exhibit elevated cancer incidence rates
It also slows the emptying of the stomach, enhancing the sensation of fullness after meals
Some studies have shown greater average weight loss with tirzepatide compared with semaglutide, but the best choice depends on the patients medical history, treatment goals, side-effect tolerance, metabolic risk, and physician evaluation
